A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Urinary Bladder Neoplasms
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 107 (final count)
- Started
- Feb 28, 2020
- Main results expected
- Jul 12, 2024
- Fully finished
- Feb 27, 2025
- Results posted
- Aug 1, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Cohort 1: Recurrence-Free Survival (RFS)
Measured over: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04172675 · record last updated 2026-02-24 · checked 2026-11-09 15:47 UTC